During the 2025 ESMO Congress, the first and only ESMO-authorized “ESMO China Focus” Uro-Oncology Session was successfully held on October 19 in Berlin. The forum highlighted major advances in urothelial carcinoma and prostate cancer, bringing together Chinese and international experts for in-depth academic discussions and intellectual exchange. Experts agreed that data from landmark studies such as EV-302 and EV-103 firmly establish enfortumab vedotin (EV)–based combination therapy as the new first-line standard of care for locally advanced or metastatic urothelial carcinoma (La/mUC). In addition, androgen-receptor pathway inhibitors (ARPI), represented by enzalutamide—which remains the only ARPI with 8-year overall-survival follow-up—continue to redefine long-term survival expectations for patients with prostate cancer, marking a new era for uro-oncology.
